Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557680 | 1.00 | GPR119 (0.41) | GPR119GAAALOX12THRATHRB | |
| SCHEMBL558014 | 0.96 | PPARA (0.44) | GPR119GAAALOX12THRATHRB | |
| SCHEMBL2926216 | 0.89 | PLA2G2A (0.35) | GPR119ALOX12THRBKMT2ASMN1; SMN2 | |
| SCHEMBL1743025 | 0.85 | CYP4A11 (0.39) | THRATHRBKMT2ASMN1; SMN2 | |
| SCHEMBL557854 | 0.85 | ITGB3 (0.36) | THRATHRBKMT2AHRH2HRH1 | |
| SCHEMBL557969 | 0.85 | ITGB3 (0.36) | THRATHRBKMT2AHRH2HRH1 | |
| SCHEMBL10099812 | 0.85 | ITGB3 (0.36) | THRATHRBKMT2AHRH2HRH1 | |
| SCHEMBL1362154 | 0.85 | ITGB3 (0.37) | HRH2HRH1 | |
| SCHEMBL4087824 | 0.85 | ITGB3 (0.38) | GPR119THRATHRBHRH2HRH1 | |
| SCHEMBL2925326 | 0.81 | CNR1 (0.42) | SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386572-B1 | Insulin derivative | NOVO NORDISK AS (DK) | 2015-07-08 | — | — | EP | disclosed |
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| EP-2015770-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2012-09-26 | — | — | EP | disclosed |
| EP-2386572-A1 | Insulin derivative | Novo Nordisk A/S (DK) | 2011-11-16 | — | — | EP | disclosed |
| US-8039101-B2 | Radio-opaque dental prosthetic member | Societe de Recherches Techniques Dentaires-R.T.D. (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| EP-2015770-A2 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007128817-A2 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | IAPP, INSR, GPR119 | GPR119 3/4885GAA 444/4885ALOX12 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.